Name: 5th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress-EU/UK [Time Zone- Central European Time]
Start: 2021-10-26
End: 2021-10-28

EVENT OVERVIEW

Our 5th Annual MarketsandMarkets Next Gen Immuno-Oncology Virtual Congress to be held on 26 - 29 October 2021 would address the challenges and future directions in IO research. The congress aims to bring academicians, researchers and scientists from research institutes pharmaceutical, bio-pharmaceutical and biotechnology companies to discuss the latest updates in development of ADC’s, Bispecific Antibodies, Cellular Therapy and Immune Checkpoint Inhibitors.

With more than 20 speakers across the world from pharma, bio-pharma and biotech companies, the congress will discuss the latest updates in development of ADC’s, Monoclonal Antibodies, Bispecific Antibodies, Immune Checkpoint Inhibitors and Cellular Therapy

Meet and network with experts from leading universities and industry sharing their knowledge on Preclinical and Translational Immuno-Oncology Developments, Next Gen CAR-T Cell Therapy, Immune Checkpoint Inhibitors, Monoclonal and Bispecific Antibodies and more.

A platform to meet experts from Pharma, bio-pharma and biotech companies and increase your learning in Monoclonal and Bispecific Antibodies, Cell Therapy and Immune Checkpoint Inhibitors.

This congress would also focus on various combination strategies, pre-clinical and translational immune-oncology developments, updates in cellular and viral therapies, vaccines development and personalized immunotherapy. Keynote presentations, Brainstorming Panel Discussions and Case studies will give the stakeholders an opportunity to discuss and understand the issues faced and come up with solutions.

Updates in development of ADC’s and Bispecific Ab’s
Immune Checkpoint Inhibitors and Combinations
Preclinical and Translational Immuno-Oncology Developments (Preclinical models for Immune checkpoint modulators)
Biomarkers and Personalized Medicine in IO
CAR-T Cell therapy, TCR Based-Cell Therapy
Tumor microenvironment and Oncolytic Viruses

CSO, Director, VP, Head, Senior Investigator, Manager, Principal Scientist, Team Leader, Group Leaders, Professors, Assistant Professors, Research fellows, PhDs working on

Monoclonal and Bispecific Antibodies
Cell Therapy
Immune Checkpoint Inhibitors

Exclusive conference to learn about antibodies, cellular therapy and immune-checkpoint research under one roof
Find out new case studies of immune-oncology projects in development
Contribute to interactive roundtables with your peers to deliberate key topics most relevant to you
Explore the latest platforms and technologies on the market for development
Discuss the best tool for your research in immune-oncology
Share your work and achievements with your industry peers in the Poster Session

CONFERENCE AGENDA

Registration	14:00 - 14:20
Welcome note from MarketsandMarkets	14:20 - 14:25
Opening remarks from the Chairman Mahendra Deonarain, Chief Executive and Science Officer, Antikor Biopharma	14:25 - 14:30
Keynote Presentation: Anti-glycan mabs linked to duocarmycin and PBD payloads as potent drug conjugates Lindy Durrant, Professor of Cancer Immunotherapy, CEO, ScanCell Ltd	14:30 - 15:00
NEXT GEN TARGETED THERAPEUTIC ANTIBODIES AND TUMOR MICROENVIRONMENT
Enhanced Biomarker Discovery and Validation Using TMT® Proteomics Ian Pike, Chief Scientific Officer, Proteome Sciences PLC	15:00 - 15:30
Immunogram & Atlas: An Integrated Multi-Omic Approach and Database to Interrogate the Tumor Microenvironment and Guide CDx Development” Corinne Danan, General Manager, Biopharma, Veracyte	15:30 - 16:00
Customized Recombinant Proteins and Antibodies of Broad-Spectrum to Accelerate Immuno-Oncology Research Linlin Zhang, Technical Specialist, Sino Biological	16:00 - 16:30
Networking and One-on-One Meetings on the event portal	16:30 - 16:45
Characterizing NSCLC tumor microenvironment using the integrated MultiOmyxTM-RNAscope® workflow Courtney Todorov, Senior Scientist, NeoGenomics	16:45 - 17:15
Two Sides of the same Coin - ImmunoID NeXT and NeXT Liquid Biopsy: Comprehensive Platforms for Tumor Immunogenomics Maik Pruess PhD, Senior Field Application Scientist , Personalis Inc	17:15 - 17:45
Assessing Treatment Benefit in Immuno oncology Laurence Collette, Principal Statistician, Consulting Services, IDDI	17:45 - 18:15
BIG QUESTIONS, SIMPLE SOLUTIONS: Spatial biology in a few and automated steps Barbara Cahill, Sr. Global Portfolio Manager for Immunohistochemistry, Consumables and Cytology, , Epredia	18:15 - 18:45
Complete Genomic Profiling for Global Clinical Trials including bTMB Reed Selby, Director of Biopharma Business Development, Predicine	18:45 - 19:15
Modulation of tumor micro-environment by the oncolytic adenovirus ONCOS-102 Victor Levitsky, Chief Scientific Officer, Targovax	19:15 - 19:45
Closing remarks from Chairman	19:45 - 19:50
End of Day 1 and One-one-One Networking	19:50 - 19:55

Registration	14:00 - 14:20
Welcome note from MarketsandMarkets	14:20 - 14:25
Opening remarks from the Chairman	14:25 - 14:30
Keynote Presentation: Neoantigen Targeted Cancer Immunotherapy in the Clinic Matt Davis, Director, Molecular Biology & Sequencing, Gritstone Oncology, Inc.	14:30 - 15:00
TCR BASED AND CAR-T CELLULAR THERAPY IN IMMUNO-ONCOLOGY
Humanized Mouse Models for Immuno-Oncology Research Kiave-Yune HoWangYin, PhD , Research and Development Director, Transcure Bioservices	15:00 - 15:30
Allogenic Off the Shelf CAR T Cell Therapy Maurizio Chiriva-Internati, Chairman, CEO, Kiromic	15:30 - 16:00
Bioprinted Assembloids: The Next Generation of 3D Tumor Models Priyanka Koti, Bioink Production Engineer, CELLINK	16:00 - 16:30
Networking and One-on-One Meetings on the event portal	16:30 - 16:45
Next generation CAR T cells engineered for enhanced safety and efficacy in solid tumors Melita Irving, Group Leader, Human integrated tumor immunology discovery engine (Hi-TIDe), Ludwig Institute for Cancer Research	16:45 - 17:15
Humanized mouse model choices for immuno-oncology drug efficacy and toxicity evaluation Juan Liang, Scientist, R&D, GemPharmatech	17:15 - 17:45
Functional phenomics enabling comprehensive analysis of cancer-immune cell interactions at single-cell resolution Robert Weingarten, CSO & Co-Founder, Evorion Biotechnologies	17:45 - 18:15
Next-Generation Humanized Mice Improve Translation of Novel Immunotherapies Jenna Frame, Senior Scientist, Scientific Communications, Biocytogen	18:15 - 18:45
TNFR2 Antagonism and the Tumor Microenvironment Russell LaMontagne, President, CEO, Boston Immune Technologies & Therapeutics	18:45 - 19:15
Nanopore technology - transforming genomics and transcriptomics Miten Jain, Assistant Research Scientist, University of California Santa Cruz	19:15 - 19:45
Closing Remarks from Chairman	19:45 - 19:50
End of Day 2 and One-one-One Networking	19:50 - 19:50

Registration	14:00 - 14:20
Welcome note from MarketsandMarkets	14:20 - 14:25
Opening remarks from the Chairman	14:25 - 14:30
Keynote Presentation: Precision Medicine Informed Immuno-Oncology is Transforming Cancer Therapy	14:30 - 15:00
ADVANCING PRECISION MEDICINE, BIOMARKERS AND PRECLINICAL DEVELOPMENTS IN IMMUNO-ONCOLOGY
Navigating the Landscape - Curating and Digitizing Public Clinical Trial Data Mark Gramling, PhD, Director, Oncology, Larvol	15:00 - 15:30
T-cell homing in cancer immunotherapy Ann Ager, Professor, Cellular Immunity and Immunotherapy, Cardiff University	15:30 - 16:00
Spatial insights into the complexity of the tumor microenvironment Bonnie Phillips, P.hd, Director Field Application Scientist, Ultivue	16:00 - 16:30
Advantages of vaccines over other Immuno-Oncology products John Maudsley, CEO, Cancer Vaccines Ltd	16:30 - 17:00
Discovery and Development of Novel Antibody Fragment Drug Conjugates for Solid Tumours Mahendra Deonarain, Chief Executive and Science Officer, Antikor Biopharma	17:00 - 17:30
Therapy of advanced non melanoma skin cancers (NMSC) with ICI: What are the advantages and why? Stefan Glueck, Senior Vice President, Global Medical Affairs, Celgene	17:30 - 18:00
Advancing immune-oncology drug development with single cell sequencing Ning Wang, Bioinformatics Lead, Arcus Biosciences	18:00 - 18:30
Clinical implementation of SMRT sequencing for Precision Medicine in Immune diseases Paul ‏Keown, Professor of Medicine, University of British Columbia	18:30 - 19:00
Local delivery of anti-PD L1 nanobodies overcomes poor antibody penetration and allows improved blocking of PD-L1 at the tumor site Jingjing Zhu, Senior Research Scientist, Ludwig Institute for Cancer Research	19:00 - 19:30
Closing remarks from Chairman	19:30 - 19:35
End of Day 3 and One-one-One Networking	19:35 - 19:35